NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors ...

The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. . Shareholders who purchased shares of MRK ...

NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

HPV, one of the most prevalent sexually transmitted infections, is the cause of nearly 36,000 cancer cases each year in the United States.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Recent market volatility notwithstanding, equities generally deliver solid returns over long periods, like a decade. The key ...

Bernstein Liebhard LLP reminds Merck investors of an April 14, 2025 deadline to join a securities fraud class action lawsuit.

On the other hand, Merck faces greater headwinds. Disappointing sales for its Gardasil vaccine against human papillomavirus ...

When topline phase III data was released in November, hinting at the potential of success, Jefferies analyst Akash Tiwari ...

Despite this potential, the stock has fallen by 25% in the past 12 months -- so is it a bargain buy right now? During the ...

We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.